HCW Biologics files preliminary S-1 for resale of shares under Equity Purchase Agreement with Square Gate Capital

HCW Biologics Inc.

Entered Equity Purchase Agreement and Registration Rights Agreement with Square Gate Capital Master Fund on Feb 20, 2025.
Filed preliminary S-1 with SEC on April 4, 2025 for resale of Commitment Shares and future issuances.
SEC letter on April 8, 2025 confirmed it will not review the registration statement.
Company will request SEC accelerate effectiveness to on or about April 16, 2025.
Final prospectus to be filed under Rule 424(b)(3) promptly after effectiveness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.